Fig. 2From: Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United StatesDeterministic sensitivity analysis. Orange bars represent the upper bound of each parameter varied. Blue bars represent the lower bound of each parameter varied. ICER, incremental cost-effectiveness ratio; PD, progressive disease; PF, progression-freeBack to article page